Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Black Diamond Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 100,985 | $245,393.74 | $181,268.07 | -$64,125.67 | -26.13% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 15,200 | $32,376 | $27,132 | -$5,244 | -16.2% |
| EY Ellen York T. Rowe Price Investment Management Inc. | 10.56M | $27.93M | $19.07M | -$8.86M | -31.73% |
 Li Peng China Universal Asset Management Co. Ltd. | 10,111 | $24,321.63 | $18,149.24 | -$6,172.39 | -25.38% |
| SR Sean Reitenbach Prosperity Consulting Group LLC | 11,355 | $24,186.15 | $20,552.55 | -$3,633.6 | -15.02% |
Black Diamond Therapeutics, Inc. (BDTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Black Diamond Therapeutics, Inc. ever had a stock split?
Black Diamond Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark A. Velleca CEO | NASDAQ (NGS) Exchange | 09203E105 CUSIP |
| US Country | 21 Employees | - Last Dividend | - Last Split | 30 Jan 2020 IPO Date |
Overview
Black Diamond Therapeutics, Inc. is a clinical-stage company dedicated to oncology medicine, with a sharp focus on developing MasterKey therapies for patients harboring genetically defined tumors. Initially known as ASET Therapeutics, Inc., the company underwent a name change to Black Diamond Therapeutics, Inc. in January 2018, marking a new chapter in its journey to combat cancer. Since its inception in 2014, the company has been on a mission to unlock new possibilities in cancer treatment, operating out of its headquarters in Cambridge, Massachusetts. By zeroing in on genetically defined tumors, Black Diamond Therapeutics aims to pave the way for more personalized, effective cancer treatments.
Products and Services
-
BDTX-1535
This brain-penetrant epidermal growth factor receptor (EGFR) MasterKey inhibitor stands as Black Diamond’s lead product candidate. It is currently undergoing a phase 2 clinical trial aimed at treating epidermal growth factor receptor mutant non-small cell lung cancer. Additionally, BDTX-1535 is in a phase 1 clinical trial for the treatment of glioblastoma, showcasing the company’s commitment to addressing some of the most challenging cancer types with innovative approaches.
-
BDTX-4933
Another promising candidate from Black Diamond’s portfolio is BDTX-4933, a brain-penetrant RAF MasterKey inhibitor. This investigational drug targets alterations in KRAS, NRAS, and BRAF found within solid tumors. Currently, BDTX-4933 is in a phase 1 clinical trial, reflecting an important step in the company’s efforts to broaden its impact on cancer treatment through cutting-edge research and development.
-
BDTX-4876
BDTX-4876 represents a significant stride in the field of cancer treatment as a MasterKey inhibitor of oncogenic FGFR2/3 mutations. It exhibits selectivity towards FGFR1/4 mutations and is in the preclinical stage of development. As the company advances BDTX-4876 through the necessary trials and regulatory processes, it holds the potential to become a vital tool against cancers driven by specific genetic alterations.
